Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). Prognostic biomarkers are an unmet need.
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score
Personeni, Nicola;Rimassa, Lorenza;
2022-01-01
Abstract
Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). Prognostic biomarkers are an unmet need.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Scheiner_CRAFITY_HCC_J Hepatol_2021.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
8.73 MB
Formato
Adobe PDF
|
8.73 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
